Condition
ISS Stage III Plasma Cell Myeloma
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Active Not Recruiting1
Recruiting1
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02727803Phase 2Recruiting
Personalized NK Cell Therapy in CBT
NCT05497804Phase 2Active Not RecruitingPrimary
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
NCT03267888Phase 1Completed
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
NCT01619761Phase 1Unknown
NK Cells in Cord Blood Transplantation
Showing all 4 trials